5 - Contents

6-7 NEWS
Sanofi acquires Kadmon Holdings; Roche’s Genentech signs $3bn Adaptimmune deal

8-9 NEWS
Biogen CEO admits Aduhelm challenges; Novartis’ Kisqali data in breast cancer

10-11 CORONAVIRUS NEWS
Boosters approved in the UK and the US; Gilead's remdesivir cuts risk of severe COVID-19 by 87%

12 DARWIN'S MEDICINE
Biotech's golden non sequitur – life sciences clusters have their pros and cons

13 POLICY AND PUBLIC HEALTH
The right call – Biden’s vaccine mandate is long overdue, but it’s not a panacea

14 'HEARD' MENTALITY
Talking about mental health again seems timely as we start to head back to the office

15 PHARMA MARKETERS' BLOG
How strong is your brand?

16-17 ALZHEIMER’S DISEASE AND BEYOND
Pathology-based drug development, precision medicine and a diversification of targets all herald a promising future for therapies in neurodegeneration

18-19 THE FUTURE OF NEW MEDICINE DEVELOPMENT AND FIRST IN-HUMAN STUDIES
Assessment of new gene-based therapies is radically reshaping the way first-in-human clinical studies are delivered and the UK is leading the way

20-21 FOLLOWING THE SCIENCE OF RESPIRATORY MEDICINE
How GSK is continuing to advance the science of respiratory medicine and how, in response to the pandemic, the company has adapted in order to continue supporting patients

22-29 EMBRACING VIRTUAL PATIENT CARE
The arrival of COVID-19 has accentuated the benefits of a virtual care approach for pharma

26-28 CURB YOUR CONSERVATISM
As creativity starts gathering speed, now is the time for pharma to move out of its comfort zone

32-33 EMBRACING WHAT LIES BEYOND THE BUBBLE
The impact on individuals, teams and cultures of trying something new or doing something you didn’t think you could can be huge

34-35 MASTERING KNOWLEDGE
Strategy expertise is built on knowledge management

36-37 FINDING THE FUTURE LEADERS OF OUR INDUSTRY
How a graduate scheme is inspiring the next generation of pharma and biotech leaders

41 HEALTHCARE COMMS
OPEN Health acquires ARK, Resonant Group announces Anthem Public Relations

42 PEOPLE
Q&A with Stephen Page

October 2021